Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine...